25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
A federal district court found that the new California law barring mandatory employment arbitration ...
Read More >
Last week, the U.S. Department of Labor’s Wage and Hour Division adopted final regulations revising...
Read More >
Three Critical Steps for Ensuring Business Continuity - As of today, there are reportedly more tha...
Read More >
In light of several recent immigration-related developments, we are providing an update on the follo...
Read More >
An institution’s trade secrets generally include confidential information with commercial value. Tr...
Read More >
Officer Was Subjected to Sexual Harassment, Retaliation and Finally Constructive Discharge, Federal ...
Read More >